Frontlight ResearchEarly access
Mild cognitive impairment trials in Japan
3 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku, Mie, Okayama, Osaka, Tokyo, Yamagata
- Age
- 50 years to 90 years
- People
- 80,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - Phase 2Taking peopleA Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Where
- Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki, Nagoya, Ōbu, Suita, tabashi City, Tachikawa, Toride, Yokohama, Yufu
- Age
- 55 years to 85 years
- People
- 350 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07589595 - Phase 1Taking peopleA First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Where
- Bunkyō City
- Age
- 50 years to 85 years
- People
- 56 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06297590 · EU 2024-510604-37-00